Bird M C, Bosanquet A G, Forskitt S, Gilby E D
Bath Cancer Research Unit, Royal United Hospital, England.
Cancer. 1988 Mar 15;61(6):1104-9. doi: 10.1002/1097-0142(19880315)61:6<1104::aid-cncr2820610609>3.0.co;2-6.
A short-term differential staining cytotoxicity (DiSC) assay was used to assess the sensitivity of tumor cells in vitro from patients with chronic lymphocytic leukemia (CLL) and non-Hodgkin's lymphoma to various cytotoxic drugs. The results have been correlated with drug sensitivities of the tumors in vivo. The chemosensitivity in vitro of eight patients with CLL was observed for 12 to 42 months. In 44 cases the assay correctly predicted seven sensitive and 30 resistant tumors (84% positive correlations). There were six false predictions of sensitivity and one false prediction of resistance. Repeated testing of patients receiving treatment revealed significant and progressive development of drug resistance, while serial tests on untreated patients with CLL gave unaltered results. The development of cross-resistance to structurally related drugs was observed after treatment and many samples showed a high level of cross-resistance. However, teniposide showed greater activity than etoposide, and mitoxantrone showed greater activity than the anthracyclines. The high level of agreement between laboratory and clinical results suggests that the DiSC assay may have a useful place (1) in guiding the clinician in the selection of drugs for chemotherapy and (2) in giving an added indication of prognosis for an individual with a lymphatic neoplasm.
采用短期差异染色细胞毒性（DiSC）试验评估慢性淋巴细胞白血病（CLL）和非霍奇金淋巴瘤患者肿瘤细胞在体外对各种细胞毒性药物的敏感性。已将结果与肿瘤在体内的药物敏感性相关联。观察了8例CLL患者体外化学敏感性12至42个月。在44例病例中，该试验正确预测了7例敏感肿瘤和30例耐药肿瘤（阳性相关性为84%）。有6例假阳性敏感性预测和1例假阴性耐药性预测。对接受治疗的患者进行重复检测发现耐药性显著且呈进行性发展，而对未经治疗的CLL患者进行系列检测结果未改变。治疗后观察到对结构相关药物的交叉耐药性发展，许多样本显示出高水平的交叉耐药性。然而，替尼泊苷显示出比依托泊苷更强的活性，米托蒽醌显示出比蒽环类药物更强的活性。实验室结果与临床结果的高度一致性表明，DiSC试验可能在以下方面具有有用的作用：（1）指导临床医生选择化疗药物；（2）为淋巴系统肿瘤患者提供额外的预后指标。
